Expert Perspectives on the Clinical Impact of Non-Medical Therapeutic Switching

Adam Friedman, MD, FAAD defines non-medical therapeutic switching and discusses common tactics payors use to pressure practitioners and patients to switch.

An expert in dermatology discusses the potential impact of non-medical switching to biosimilars and generic formulations on safety and efficacy profiles.

Adam Friedman, MD, FAAD provides insight into how non-medical therapeutic switching affects clinical, economic, and psychological outcomes for patients.

A key opinion leader emphasizes the importance of discouraging non-medical switching by communicating with patients and partnering with industry researchers.

Adam Friedman, MD, FAAD discusses how payors accelerated non-medical switching during COVID-19 and how healthcare providers can respond to new challenges.